ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm 
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties 
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift 
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow 
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims 
OpenAI Explores Massive Funding Round at $750 Billion Valuation 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
CAMBRIDGE, Mass., Aug. 30, 2017 -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers for patient enrichment, today announced that Richard Murray, Ph.D., chief executive officer of Jounce, will present at two upcoming investor conferences:
- Baird 2017 Global Healthcare Conference at 12:15 p.m. ET on Wednesday, September 6, 2017 in New York, NY
- 2017 Wells Fargo Healthcare Conference at 8:15 a.m. ET on Thursday, September 7, 2017 in Boston, MA
A live webcast of each presentation will be available by visiting “Events and Presentations” in the Investors and Media section of Jounce’s website at www.jouncetx.com. A replay of the webcasts will be archived for 30 days following each presentation.
About Jounce Therapeutics
Jounce Therapeutics, Inc. is a clinical stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long‑lasting benefits to patients. Through the use of its Translational Science Platform, Jounce first focuses on specific cell types within tumors to prioritize targets, and then identifies related biomarkers designed to match the right therapy to the right patient. Jounce’s lead product candidate, JTX-2011, is a monoclonal antibody that binds to and activates ICOS and is currently in a Phase 2 trial. For more information, please visit www.jouncetx.com.
Media Contact: Katie Engleman Pure Communications, Inc. (910) 509-3977 [email protected] Investor Contact: Beth DelGiacco Stern Investor Relations, Inc. (212) 362-1200 [email protected]
